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ABSTRACT: This work assesses the urinary metabolite signature of prematurity in
newborns by nuclear magnetic resonance (NMR) spectroscopy, while establishing the role
of possible confounders and signature speciﬁcity, through comparison to other disorders.
Gender and delivery mode are shown to impact importantly on newborn urine
composition, their analysis pointing out at speciﬁc metabolite variations requiring
consideration in unmatched subject groups. Premature newborns are, however,
characterized by a stronger signature of varying metabolites, suggestive of disturbances in
nucleotide metabolism, lung surfactants biosynthesis and renal function, along with
enhancement of tricarboxylic acid (TCA) cycle activity, fatty acids oxidation, and oxidative
stress. Comparison with other abnormal conditions (respiratory depression episode, large
for gestational age, malformations, jaundice and premature rupture of membranes) reveals
that such signature seems to be largely speciﬁc of preterm newborns, showing that NMR
metabolomics can retrieve particular disorder eﬀects, as well as general stress eﬀects. These
results provide valuable novel information on the metabolic impact of prematurity, contributing to the better understanding of its
eﬀects on the newborn’s state of health.
KEYWORDS: urine, newborn, prematurity, respiratory depression, large for gestational age, malformations, metabolomics, NMR
■ INTRODUCTION
Metabolomics is an exquisite tool used to measure the
metabolic adaptations of the human organism to disease and
seek valid metabolite signatures, potentially translatable into
disease biomarkers. In newborn health research, metabolomic
studies have involved nuclear magnetic resonance (NMR)
spectroscopy (μM-mM detection limit) and mass spectrometry
(MS) (<pM detection limit) of umbilical cord blood collected
at the time of birth, newborn dried blood spots and urine, as
reviewed recently,1,2 along with a recent study of meconium in
relation to newborn urine.3 These studies have attempted to
measure the metabolic eﬀects associated with several newborn
conditions, in order to deﬁne new metabolic biomarkers, which
may be included in improved health management schemes for
newborns. Analysis of umbilical cord blood provides a snapshot
of maternal-fetal symbiosis, and compositional changes have
been detected in relation to (1) perturbations in fetal growth,
namely small for gestational age (SGA),4 intrauterine growth
restriction (IUGR),5,6 low birth weight (LBW),7 and very low
birth weight (VLBW);8 (2) hypoxic ischemic encephalopathy
(HIE) and asphyxia;9−11 (3) gestational diabetes mellitus
(GDM) pregnancies3,12) delivery mode (vaginal delivery vs
cesarean section).13 In addition, newborn blood spots collected
during the ﬁrst week of life and analyzed by1H NMR and
nanospray ionization with high resolution mass spectrometry
(nS-HR-MS) have been studied for the screening of inborn
errors of metabolism (IEM).14−16 The noninvasive collection of
newborn urine and subsequent ease to address large cohorts,
compared to newborn blood, makes it a particularly interesting
bioﬂuid in the present context. This has indeed been
recognized in reports on the newborn urinary impact of
prematurity,17−20 IUGR,21−23 large for gestational age
(LGA),22,23 GDM,3 asphyxia,11,24,25 respiratory distress syn-
drome (RDS),24 meconium aspiration syndrome (MAS),24
bronchopulmonary dysplasia,26 IEM,27 neonatal sepsis,28
postnatal bacterial,19 cytomegalovirus,29 and fungal30 infections.
Most of these studies have considered relatively small cohorts
(up to ca. 20 disease samples), with a few studies comprising
higher sample numbers.3,20,21,25 Furthermore, speciﬁc needs
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have been identiﬁed in order to enable the applicability of
newborn metabolic biomarkers in the clinic, namely the need to
adequately validate the new ﬁndings (at both statistical and
biochemical levels), gauge the impact of potential confounders
(e.g., gender, delivery mode, early nutrition, ethnicity) and
evaluate biomarker speciﬁcity to disease. In any case, some
evidence of metabolic disturbances has already been identiﬁed,
namely for newborns aﬀected by prematurity (impact on renal
and liver function, neuronal development, and amino acids
metabolism);17−20 GDM (disruption of lipid, amino acid, and
nucleotide metabolisms3); asphyxia, RDS and MAS (changes in
glucose, lactate, tricarboxylic acid (TCA) cycle metabolites and
organic acids11,24,25); and IUGR (changes in insulin secretion,
protein synthesis and catabolism, lipid synthesis, and cell
proliferation31).
In this paper, we report, for the ﬁrst time to our knowledge,
the eﬀects of important possible confounders on the urine
metabolome of healthy newborns, namely, gender, delivery
mode (previously studied through umbilical cord blood only13),
gestational age at birth and day-of-life at collection. Taking
these eﬀects into account, the impact of prematurity on
newborn urine composition is then assessed, building up on
previous studies,17−20 and compared to several other disorders
(namely respiratory depression: newborns requiring reanima-
tion after birth; LGA: birth weight above 90th percentile;
malformations; jaundice: hyperbilirrubinemia requiring photo-
therapy; and premature rupture of membranes (PROM): labor
after 37th g.w.), in order to assess signature speciﬁcity to
prematurity. To our knowledge, this is the ﬁrst report to
consider several newborn conditions concomitantly, to enable
disease-speciﬁc changes to be identiﬁed (apart from general
stress eﬀects on the newborn), while exploiting the use of a
variable selection methodology32 to reduce NMR data sets and
strengthen the predictive power of multivariate analysis models,
thus aiding in the identiﬁcation of relevant biomarker
signatures.
■ EXPERIMENTAL SECTION
Samples
Newborn urine samples were collected at the Maternity Bissaya
Barreto, University Hospital Center of Coimbra (CHUC),
under CHUC ethical committee approval (refs.18/04 and 29/
09), with parental informed consents obtained for each infant.
Clinical information was obtained from obstetrical and neonatal
medical records and individual questionnaires ﬁlled at the time
of collection. Table 1 lists sample numbers for all groups (total
n = 148) as well as corresponding day of life at sampling,
gestational age at birth, birth weight, maternal age, gravidity
(no. pregnancies), and parity (no. deliveries). Most subjects
were breastfed, with the following exceptions: n = 4 fed with
formula milk (three controls and one LGA) and n = 15 fed with
a mix of maternal/formula milk (one control, six premature
newborns, six LGA and two respiratory depression). The
control group comprised healthy term newborns (n = 46), born
from healthy mothers and normal pregnancies; for this group,
Table 1. List of Newborn Urine Samples Collected for Each Group of Healthy and Pathological Cases, Along with
Corresponding Day of Life at Sampling (Days) Gestational Age Range (Gestational Weeks, g.w.), Birth Weight Range (in
Kilograms, kg) and Maternal Age Range (Years) (top)f
aThe prematurity includes one case of SGA. bConditions observed to have a large impact on newborn urinary metabolome. c.dGroups matched for
delivery mode and gender, respectively. eExact day of collection not speciﬁed. fSamples used for investigation of potential confounding eﬀects are
also listed (control samples only). Median values are shown between brackets. PROM: premature rupture of membranes, LGA: large for gestational
age, GA: gestational age, VD: vaginal delivery, CS: cesarean section.
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the impact of gender, delivery mode (vaginal delivery (VD) or
cesarean section (CS)), age (day 1 or day 2, other days not
studied due to low number of samples), and gestational age at
birth (37 to 41 gestational weeks, g.w.) on urine composition
were investigated. Newborn urine collected for disorders
included (1) late premature newborns (birth ranging from 33
to 36 g.w., n = 17), (2) newborns having experienced a
respiratory depression episode after birth (newborns requiring
reanimation after birth, either using oxygen or air), n = 10), (3)
LGA newborns (birth weight >90th percentil, n = 18), (4)
malformed newborns (n = 9 including 1 major malformation:
situs inversus with dextrocardia, and 8 minor malformations: 5
cardiac, 2 soft tissues, and 1 urogenital), (5) PROM (labor after
37th g.w., n = 33) and (6) newborns developing jaundice 1−2
days af ter collection and requiring phototherapy, n = 12.
Urine was collected using the cotton-ball method, consisting
of the placement of a sterile cotton-ball inside the newborns
diaper, for up to 3 h, to retain urine (approximately 1.5 mL).
Urine was transferred to a sterile vial and frozen at −20 °C for
up to 24 h and then transferred to −80 °C until analysis.
Samples were thawed and 600 μL were centrifuged (4500g, 5
min). Then, 60 μL of 1.5 M KH2PO4/D2O buﬀer pH 7, 0.1%
Na+/3-trimethylsilyl-propionate (TSP) were added to 540 μL
of supernatant, followed by pH readjustment to 7.00 ± 0.02
with KOD (4 M) and/or DCl (4 M). The mixture was
centrifuged (4500g, 5 min) and 550 μL of the supernatant were
transferred to a 5 mm NMR tube.
NMR Spectroscopy
NMR spectra were recorded on a Bruker Avance DRX 500
spectrometer at 300 K. Standard 1D spectra were acquired
using a noesy 1D pulse sequence with a mixing time tm of 100
ms, a ﬁxed delay t1 of 3 μs, and water suppression during
relaxation delay and mixing time. 128 transients were acquired
into 64 k complex data points, with a 10080.65 Hz spectral
width, a 4 s relaxation delay and a 3.25 s acquisition time. Each
free induction decay was multiplied by a 0.3 Hz exponential
line-broadening function prior to Fourier transformation. The
spectra were manually phased and baseline corrected and
chemical shifts referenced internally to TSP at δ = 0.0 ppm.
Peak assignments were carried out with basis on literature, 2D
NMR experiments (total correlation spectroscopy, TOCSY and
heteronuclear single quantum coherence, HSQC), consultation
Figure 1. (a) Average 500 MHz 1H NMR spectra of female and male newborns with indication of major visual changes (see arrows), (b) PLS-DA
scores scatter plots obtained (with variable selection) for newborns urine in relation to gender (left): male (■, n = 23) vs female (□, n = 23), and to
delivery mode (right): vaginal delivery (VD) (●, n = 29) vs cesarean section (CS) (○, n = 17). Legend: 1:3-aminoisobutyrate, 2:3-hydroxybutyrate
(3-HBA), 3: lactate, 4: threonine, 5: alanine, 6: adipate, 7: acetate, 8: acetone, 9: succinate, 10: citrate, 11: dimethylamine (DMA), 12:
methylguanidine, 13: dimethylglycine (DMG), 14: taurine, 15: creatine, 16: glucose, 17: lactose, 18: fumarate, 19: N-methyl-2-pyridone-5-
carboxamide (2-Py), 20:4-hydroxyphenylacetate (4-HPA), 21: tyrosine, 22:4-hydroxyhippurate, 23:1-methylhistidine, 24: histidine, 25:
phenylacetylglutamine (PAG), 26: hippurate, 27: N-methyl-nicotinamide (NMND), 28: formate.
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of spectral databases (Bruker Bbiorefcode database and human
metabolome database, HMDB33), spectra of standard com-
pounds and statistical total correlation spectroscopy
(STOCSY).34
Statistical Analysis and Validation
Proton 1D spectra were aligned using a recursive segment-wise
peak alignment,35 normalized by probabilistic quotient normal-
ization (PQN)36 (MATLAB 7.12.0, The MathWorks Inc.) and
scaled by unit variance (SIMCA-P 11.5). Principal component
analysis (PCA) and partial least-squares discriminant analysis
(PLS-DA) were applied to the full resolution spectra (after
exclusion of water (4.62−5.05 ppm) and urea (5.65−6.00 ppm)
regions) and variable selection was performed, as described
previously.32 On average, it was found through variable
selection that 1/4 to nearly
1/3 of variables (chemical shifts)
were adequate to build classiﬁcation models with predictive
power (Supporting Information (SI) Table S2). PLS-DA model
validation was assessed for full resolution and reduced data sets,
through Monte Carlo cross validation (MCCV, in-house
developed) (7 blocks, 500 runs), with recovery of Q2 values
and confusion matrices; simultaneously, a randomized class-
permutation procedure used to assess the null hypothesis.37,38
Classiﬁcation rates (CR), speciﬁcity (spec.) and sensitivity
(sens.) were computed and model predictive power was further
complemented using a receiver operating characteristic (ROC)
map, a function of the true positive rate (TPR or sensitivity)
and false positive rate (FPR or 1-speciﬁcity). PLS-DA models
were considered satisfactorily robust when exhibiting Q2 > 0.4,
high CR, sensitivity and speciﬁcity, good quality ROC maps
and true and permuted Q2 values distributions (with >97% of
permuted models with Q2 lower than the original Q2 value). SI
Table S2 lists the model quality parameters obtained for all
PLS-DA models and robust models are shown in bold. The
Table 2. Metabolite/Resonance Changes in Newborn Urine of Infants Born through Vaginal Delivery (VD) Compared to
Cesarean Section (CS) (Left) and Females Compared to Males (Right)
aChemical shifts selected by variables selection; TOCSY or STOCSY correlated peaks in square brackets; s: singlet, d: doublet, t: triplet, q: quartet,
dd: doublet of doublets, m: multiplet, br: broad. bp-values adjusted for multiple testing according to Benjamini and Hochberg false discovery rate
correction40. cPeaks possibly related to diet and/or gut microﬂora. dConsistent with gender-speciﬁc changes reported in adults.41,42 eMetabolites
identiﬁed for the ﬁrst time in connection to gender. *Putative assignment. Ui: unassigned compound i in order of appearance. 2-KG: 2-ketoglutarate,
DMA: dimethylamine, 4-DEA: 4-deoxyerythronic acid, 4-HPA: 4-hydroxyphenylacetate, IS: indoxyl sulfate, PAG: phenylacetylglutamine, NMND:
N-methyl-nicotinamide. Eﬀect size values equal or lower than error, concomitantly with p-values > 0.05, are not shown.
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selected variables giving rise to robust PLS-DA models were
represented graphically in a variable importance to projection
(VIP)-wheel format,32 where inner and outer circles represent
the average 1H NMR spectrum of controls and corresponding
ppm scale, respectively, and the radial dimension reﬂects the
VIP value for each variable. The relevant peaks were integrated
in the full resolution spectra (Amix 3.9.5, Bruker BioSpin,
Rheinstetten, Germany) and normalized by PQN. For each
integral, statistical and biological relevancies were respectively
calculated by the Wilcoxon test (statistical relevance deﬁned as
p < 0.05) and eﬀect size (ES).39 ES represents the diﬀerence
between the averages of two groups and is computed by ES =
(X̅1 − X̅2)/((n1 − 1)s12 + (n2 − 1)s22/(n1 − n2 − 2))1/2, where X̅j,
sj, and nj represent the mean, standard deviation and sample
size of two groups (j = 1,2), respectively. P-values were
corrected for multiple comparisons using false discovery rate
correction based on Benjamini and Hochberg method.40
■ RESULTS
Eﬀects of Gender, Delivery Mode, Gestational Age, and
Day of Collection
First, the impacts of gender, delivery mode, gestational age at
birth and day of collection on newborn urine composition were
assessed, since diﬀerences in these parameters are bound to be
found in larger cohorts. The average 1H NMR spectra of
healthy female and male newborns (Figure 1a) illustrate the
high number of peaks and peak overlap typical of urine spectra.
A total of 56 metabolites were assigned (SI Table S1), including
a ﬁrst account, to our knowledge, of phenylacetylglutamine
(PAG) and indoxyl sulfate (IS) in newborn urine. Visual
inspection of the spectra in Figure 1a suggests that females’
newborn urine has higher levels of fumarate (peak 18), glucose
(peak 16), lactose (peak 17), taurine (peak 14), and threonine
(peak 4), and lower amounts of acetone (peak 8), creatine
(peak 15), and formate (peak 28) than males. PCA of the NMR
spectra showed only a vague distinction between groups (not
shown) and the corresponding PLS-DA model (not shown)
had a relatively low predictive power (Q2 0.270, SI Table S2).
Variable selection is useful to ﬁlter oﬀ random variability (i.e.,
noise) in the data and therefore retrieve consistent variations
related to the condition under study. Variable selection
produced a new PLS-DA model for gender (Figure 1b left),
with improved predictive power (Q2 0.474, SI Table S2, Figure
S1a), although of low sens., spec. and CR (75−76%). A VIP-
wheel representation (SI Figure S2a) indicated allantoin, myo-
inositol, lysine, taurine, xanthine, sugar (5.50−5.56 ppm),
purine/pyrimidine resonances (6.11−6.48 ppm), and unas-
signed resonance at δ 7.06 as important contributors toward
gender group separation. This type of representation oﬀers a
graphic description of the spectral proﬁle variations between
the groups compared. The full metabolite signature describing
the changes in female urine, compared to males, is listed in
Table 2 and comprises changes in several unassigned spin
systems (U1−U5) and regions (complex spectral segments
accommodating several overlapped resonances), with distinct
Figure 2. Average 500 MHz 1H NMR aliphatic (0.5−3.0 ppm, right) and aromatic (6.0−9.5 ppm, left) regions of urine of (a) controls, (b)
prematurity, (c) respiratory depression, (d) LGA, and (e) malformations newborn groups. Some relevant assignments are noted in (a), following the
peak numbering deﬁned in Figure 1a. Major visual changes are indicated with arrows and curved lines in b−e) for each disorder group.
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univariate statistical relevance, as also illustrated in a Volcano
plot (SI Figure S2a). Changes in acetone, dimethylamine
(DMA) and fumarate coincide with earlier reports on human
adults41−44 and changes in 10 additional metabolites (e in Table
2, left) are here reported for the ﬁrst time in connection to
gender. Overall, compared to males’, newborn females ́ urine
was conﬁrmed to comprise higher levels of 2-ketoglutarate (2-
KG), allantoin, cis-aconitate, fumarate, glucose, lactose,
methylguanidine, N-methyl-nicotinamide (NMND), taurine,
threonine, and xanthine, and lower levels of 4-OH-hippurate,
acetone, creatine, DMA, formate, galactose, hippurate, lysine,
myo-, and scyllo-inositols.
A similar strategy was followed to compare the impact of
delivery through cesarean section and vaginal delivery. Upon
variable selection, a PLS-DA model with Q2 0.523 and 79−94%
sens., spec. and CR was obtained (Figure 1b right, SI Table S2),
reﬂecting a detectable impact of delivery mode on newborn
urine composition. The corresponding VIP-wheel plot (SI
Figure S2b) identiﬁed important changes in DMA, IS, tyrosine,
trigonelline, unassigned singlets U7 and U8 (at δ 2.06 and 3.96,
respectively) and regions (bile acids, aliphatic and aromatic
resonances). Overall, variations of assigned compounds noted
in CS cases, compared to VD (Table 2, right and Volcano plot
in SI Figure S2b), bear increases in 1-methylhistidine, 2-KG,
acetone, betaine, DMA, ethanolamine, lactose, and decreases in
4-deoxyerythronic acid (4-DEA), 4-hydroxyphenylacetate (4-
HPA), cis-aconitate, IS, myo-inositol, PAG, trigonelline and
tyrosine.
Regarding gestational age at birth (from 37 to 41 g.w.) and
day of collection (days 1 and 2, only), no signiﬁcant changes in
urinary composition were noted, other aspects such as type of
anesthetics at delivery and type of feeding (maternal or formula
milk) not having been studied speciﬁcally, due to the low
sample numbers representing each condition. The eﬀects of
gender and delivery mode described above should, thus, be
considered in newborn disorder studies, particularly when
control and disease groups are unbalanced in these respects.
Eﬀects of Prematurity and Comparison with Other
Newborn Disorders
Figure 2b shows the average 1H NMR spectrum (aliphatic and
aromatic regions) corresponding to premature newborns, with
indication of apparent visual diﬀerences, compared to controls
(Figure 2a). PLS-DA of variable selected matrices clearly
diﬀerentiated the prematurity group from controls in LV1 (Q2
0.556, Figure 3a), with 92% sens., spec. and CR (SI Figure S1b
and Table S2). The results suggest that positive and negative
LV1 values reﬂect normal and disturbed metabolic proﬁles,
respectively, although a small group overlap is noted (circled
symbols in Figure 3a). It is interesting to note that such
separation is clearly not simply explained by gestational age or
birth weight (SI Figure S3), higher values of these character-
istics not translating necessarily into healthy metabolic proﬁles;
this emphasizes the importance of using metabolic proﬁles as
additional health assessment markers. Considering the whole
prematurity group, an overall metabolic signature descriptive of
the condition may be retrieved, as shown by the corresponding
VIP-wheel (Figure 4a), which reﬂects a variation ﬁngerprint
with large contributions from 3-aminoisobutyrate, 3-hydrox-
ybutyrate (3-HBA), cis-aconitate, ethanolamine, N-methyl-2-
pyridone-5-carboxamide (2-Py) and NMND along with
Figure 3. PLS-DA scores scatter plots obtained for (a) prematurity (□, n = 17), (b) newborns with respiratory depression (◇, n = 10), (c) LGA
newborns (○, n = 18), and (d) malformations (∗, n = 9) compared to controls (■, n = 46). Circles indicate outlier samples.
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unassigned U10 and U11 (singlet at δ 6.59 and doublet at δ
6.76, respectively), and several aliphatic and aromatic regions.
The overall metabolic signature of prematurity (Table 3, top
left) comprises changes in 25 identiﬁed metabolites and several
additional unassigned resonances/regions, 29 of which with
univariate statistical relevance (p-values <0.05), as illustrated on
a Volcano plot format (Figure 5a). Among these, the increase
in myo-inositol and NMND conﬁrmed previous observations (e
in Table 3).18,19 Considering that the prematurity group was
somewhat unbalanced in terms of gender (11M/6F, compared
to 23M/23F in controls), a possible contribution of gender
must be allowed for (d in Table 3) in relation to increased 4-
OH-hippurate, formate, fumarate, lysine, myo-inositol, and
decreased methyl-guanidine and xanthine.
In order to establish if the above signature is speciﬁc of
prematurity or if, on the contrary, it reﬂects general stress
eﬀects on the newborn, other disorders were investigated for
comparison. Indeed, spectral proﬁle changes were also noted
for newborns experiencing respiratory depression, LGA and
malformations (Figure 2c−e) (no relevant changes were noted
for PROM and jaundice-developing groups), but the
corresponding signatures were found to be distinct from that
of prematurity. Speciﬁcally, newborns suﬀering from respiratory
depression evidenced some PLS-DA separation from controls
(Figure 3b, SI Table S2) and, in spite of the low sample
numbers, a VIP-wheel pattern visually distinct from prematurity
was obtained (Figure 4b), thus illustrating the speciﬁcity of the
two sets of metabolite changes. Respiratory depression seems
to induce a distinct signature determined by 4-deoxythreonic
acid (4-DTA), glycine, myo-inositol, taurine, threonine, U7 (s, δ
2.06), U12 (s, δ 2.05), U14 (s, δ 2.81), U16 (s, δ 8.39), along
with several unassigned regions with no individual statistical
relevance (∗ in Figure 4b), but important as part of a
classiﬁcation proﬁle. Overall, changes in 21 identiﬁed
metabolites and several unassigned resonances/regions, 17 of
which characterized by individual statistical signiﬁcance (p <
0.05) were found to characterize respiratory depression (Table
3, top right; Figure 5b). Regarding LGA and malformed
newborns, PLS-DA performance is comparable (SI Table S2),
with clear outlier samples being noted in both cases (Figure
3c,d): in LGA, the outliers contained abnormally high levels of
unassigned resonance δ 0.70−1.07 (bile acid region19), myo-
inositol or hippurate; in malformations, the outlier evidenced
high levels of galactose. Again, the VIP-wheels (Figure 4c,d)
Figure 4. VIP-wheel representation of the NMR metabolite signatures obtained for (a) prematurity, (b) respiratory depression, (c) LGA newborns,
and (d) malformations. The average 1H NMR spectrum of controls is represented in the inner circle, with the corresponding ppm scale in the outer
circle. Each dot represents a selected variable and the VIP value is shown in the radial scale. Colored shade indicates region typically containing
resonances of bile acids (green), aliphatic region (blue), sugar region (pink), and aromatic region (orange). Metabolites or spectral regions with
higher VIP values are noted. 3-HBA: 3-hydroxybutyrate, NMND: N-methyl-nicotinamide, 4-DTA: 4-deoxythreonic acid, DMG: dimethylglycine, 2-
Py: N-methyl-2-pyridone-5-carboxamide, IS: indoxyl sulfate. ∗: spectral features corresponding to large VIP values but with no statistical relevance (p
value >0.05).
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Table 3. Metabolite/resonance changes in urine of preterm newborns (above left), newborn with respiratory depression (above
right), LGA newborns (below left) and newborns with malformations (below right) compared to controls
Prematurity (n = 17) vs Controls (n = 46) Respiratory Depression (n = 10) vs Controls (n = 46)
Compound δH/ppm and multiplicity
a Variation (effect size, p-valueb) Compound δH/ppm and multiplicity
a Variation (effect size, p-value)
1-methylhistidinec 7.78 s ↓ (−0.83 ± 0.58, 1.46e−2) 1-methylhistidinec 7.78 s ↓
2-Py 6.66 d, 8.33 d ↓ (−0.96 ± 0.58, 6.64e−3) 2-KG 2.45 t, 3.01 t ↓
3-aminoisobutyrate 1.19 d, 2.61 m, ↓ (−1.37 ± 0.61, 3.43e−5) 3-HBA 2.31 m, 2.41 m, ↓
3.06 dd 4.15 m
3-HBA 1.20 d ↓ (−0.49 ± 0.56, 1.46e−2) 3-methylhistidinec 7.15 s ↓
3-HIVA 1.27 s ↑ 4-DEA 1.11 d ↓
3-methylhistidinec 7.15 s, 8.12 s ↓ 4-DTA 1.23 d ↓
4-DTA 1.23 d ↓ (−0.61 ± 0.57, 7.84e−2) Betaine 3.26 s, 3.91 s ↑ (1.10 ± 0.71, 7.89e−2)
4-OH-hippuratec,d 7.76 d ↑ Cholinec 3.20 s ↑
Acetone 2.23 s ↓ Creatine 3.04 s, 3.93 s ↑ (0.95 ± 0.71, 7.89−2)
Cis-aconitate 3.12 d ↓ (−1.37 ± 0.61, 5.89e−5) DMA 2.72 s ↓
Citrate 2.54 d, 2.69 d ↑ Formate 8.46 s ↑
Creatine 3.04 s, 3.93 s ↓ Glycine 3.57 s ↑ (1.21 ± 0.72, 6.77e−2)
Creatinine 3.05 s, 4.06 s ↓ (−0.85 ± 0.58, 2.76e−2) Hypoxanthine 8.20 s, 8.22 s ↓
DMAc 2.72 s ↓ (−0.88 ± 0.58, 1.49e−2) IS 7.70 d ↑
Ethanolamine 3.15 t, 3.84 t ↓ (−0.97 ± 0.58, 3.57e−3) Lactosec 3.66 m, 3.79 m, ↑
Formated 8.46 s ↑ (0.89 ± 0.58, 1.49e−2) 3.94 m, 4.46 d
Fumarated 6.53 s ↑ Lysine 1.73 m, 1.92 m ↓
IS 7.51 d ↑ (1.00 ± 0.58, 7.84e−2) Myo-inositol 3.26 t, 3.55 m, ↑ (1.54 ± 0.74, 7.89e−2)
Lactate 4.11 q ↓ (−0.76 ± 0.57, 1.72e−2) 3.64 t, 4.07 t
Lysined 1.73 m ↑ (0.63 ± 0.57, 4.86e−2) Taurine 3.43 t ↑ (0.96 ± 0.71, 7.89e−2)
Methylguanidined 2.83 s ↓ (−0.78 ± 0.57, 1.46e−2) Threonine 4.26 dd ↓
Myo-inositold,e 3.26 t, 3.53 dd, ↑ (0.87 ± 0.58, 4.10e−2) Trigonellinec 4.44 s ↓
4.07 t Xylosec 5.21 d ↓
NMNDe 4.48 s, 8.90 d, ↑ (1.20 ± 0.59, 2.94e−3) U12 2.05 s ↑ (1.00 ± 0.71, 7.89e−2)
8.97 d, 9.28 s U7d 2.06 s ↓ (−0.72 ± 0.70, 9.14e−2)
Succinate 2.41 s ↑ (0.61 ± 0.57, 7.85e−2) U13 2.26 s ↓ (−0.82 ± 0.70, 1.14e−1)
Xanthine*,d 7.93 s ↓ (−0.83 ± 0.57, 8.05e−3) U14 2.81 s ↑ (0.88 ± 0.70, 9.14 e−2)
U9 4.51 s ↑ (0.67 ± 0.57, 1.35e−2) U15 2.90 s [3.94 s] ↑ (0.90 ± 0.70, 7.89e−2)
U10 6.59 s ↓ (−1.24 ± 0.60, 2.70e−4) U16 8.39 s [6.08 d] ↑ (1.10 ± 0.71, 1.18e−1)
U11 6.76 d ↓ (−1.17 ± 0.59, 7.46e−4) Unassigned spectral regions
Unassigned spectral regions 2.08−2.09 ↓ (−1.00 ± 0.71, 7.89e−2)
1.99−2.01 ↑ (0.73 ± 0.57, 3.59e−2) 2.10−2.12 ↓ (−0.85 ± 0.70, 1.14e−1)
2.75−2.79 ↓ (−1.26 ± 0.60, 8.11e−4) 2.48−2.52 ↓ (−0.79 ± 0.70, 1.14e−1)
2.89−2.92 ↓ (−1.06 ± 0.59, 1.51e−3) 6.61−6.62 ↓ (−1.03 ± 0.71,1.14e−1)
3.35−3.37 ↑ (1.05 ± 0.59, 2.08e−2) 6.63−6.68 ↓ (−1.00 ± 0.71, 1.14e−1)
7.18−7.20 ↑ (1.12 ± 0.59, 1.46e−2) +8 unassigned spin systems and 16 spectral regions with p > 0.05
+ 5 unassigned spin systems and 8 spectral regions with p > 0.05
LGA (n = 18) vs Controls (n = 46) Malformations (n = 9) vs Controls (n = 46)
Compound δH/ppm and multiplicity
a
Variation (effect size, p-
value) Compound δH/ppm and multiplicity
a
Variation (effect size, p-
value)
2-KGd 2.45 t, 3.01 t ↓ 2-Py 6.66 d, 7.97 dd, 8.33 d ↓ (−0.82 ± 0.73, 3.30e−1)
2-Py 6.66 d, 7.97 dd, 8.33 d ↑ (1.01 ± 0.57, 6.63e−2) 3-aminoisobutyrate 1.19 d, 2.61 m, 3.06 dd ↓
Alanine 1.49 d ↑
Citrate 2.54 d, 2.69 d ↓ 3-HBA 1.20 m 2.31m, 2.41 m, 4.16 m ↓
Creatined 3.04 s, 3.93 s ↑
DMG 2.93 s ↑ (0.77 ± 0.56, 5.52e−2) 4-DEA 1.11 d ↑
Fumarated 6.53 s ↓ 4-HPAc,f 6.86 d ↓
Glycine 3.57 s ↓ Acetone 2.23 s ↓
Hippuratec,d 3.97 d, 7.56 t, 7.64 t, 7.83 d ↑ Cis-aconitated,f 3.12 d ↓
Citrate 2.54 d, 2.67 d ↓
Myo-inositol 3.29 t, 3.55 t, 3.63 t, 4.08 t ↓ (−0.67 ± 0.56, 7.50e−2) Cholinec 3.20 s ↓
DMG 2.93 s, 3.72 s ↑
NMND 8.18 m, 8.90 d, 8.97 d, 9.28 s ↑ Fumarated 6.53 s ↓
Glutamine 2.11 m, 2.47 m ↑
Succinate 2.41 s ↑ Hippuratec,d 3.97 d, 7.56 t, 7.64 t ↑
Taurine 3.43 t ↑
Unassigned spectral regions ISf 7.28 m, 7.50 d, 7.70 d ↓ (−0.78 ± 0.73, 3.30e−1)
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unveiled graphically speciﬁc signatures of variations, both
distinct from prematurity. LGA cases are characterized by
variations in 13 metabolites, only 2-Py, dimethylglycine
(DMG) and myo-inositol having p < 0.05) (Table 3, Figure
5c), comprising some possible contributions from gender
unbalance (14M/4F in LGA) (d in Table 3). The urinary
signature retrieved for the malformation group (Table 3,
bottom right) comprised changes in 22 metabolites (only 2-Py,
citrate, IS and succinate having p < 0.05), unassigned U17
(singlet, δ 4.53) and region at δ 8.40−8.42, with p < 0.05
(Figure 5d), with possible contributions from gender (6 M/3
F) and delivery mode (2 VD/7 CS) (d and f in Table 3,
respectively). It is noted however that such signature is an
average description of several types of malformations,
conﬁrming previous reports of general metabolic characteristics
describing fetal malformations, as viewed by maternal urine.32
■ DISCUSSION
Figure 6 summarizes the main putative metabolic impacts on
diﬀerent metabolic pathways of gender and delivery mode, as
well as of prematurity, respiratory depression, LGA and the
heterogeneous group of malformations. Color coding by
disorder helps to acknowledge both common and speciﬁc
qualitative metabolic changes.
Gender and Delivery Mode
Regarding gender diﬀerences, variations in DMA, fumarate, and
acetone were found to coincide (in nature and direction) with
previous reports relating to adult cohorts,41,42 while creatine,
hippurate, NMND, taurine and threonine were here found to
vary in opposite directions to those reported.41−44 Other 16
metabolites reported to be gender dependent in adults were, in
the present cohort, either not detected or not seen to vary.
Adults and newborns seem, therefore, to be characterized by
distinct gender-speciﬁc excreted metabolomes. In this cohort,
the urine of females was richer in allantoin and xanthine and
showed lower intensity in purines/pyrimidines region (δ 6.46−
6.48), thus suggesting altered purine degradation and general
nitrogen base metabolism in females, compared to males. In
addition, higher levels of glucose and lactose, along with lower
levels of inositols and other sugar resonances (δ 5.50−5.56),
were indicative of changes in sugar metabolism associated with
gender in the ﬁrst days of life. Myo-inositol can be
endogenously synthesized from glucose and is converted to
scyllo-inositol in the gut microﬂora.45 Here, this process seems
to be hindered in females, resulting in a lower utilization of
glucose for inositol production. As no reports were found on
diﬀerences in gender-related sugar and nucleotide metabolism
in adults, it is suggested that these diﬀerences may be unique to
this early age. Figure 6 (light pink arrows) shows that additional
smaller changes are also observed in female newborns,
compared to males, in relation to creatinine biosynthesis,
methionine cycle and TCA cycle. Diﬀerences found in relation
to delivery mode are consistent with previous knowledge of (1)
lower gut microﬂora colonization in caesarian section cases, (2)
increased stress associated with labor, and (3) possible
alterations in hepatic metabolism.46−49 Babies born through
CS have reduced bacterial content and delayed appearance of
some bacterial species46 and this may explain the decreased
levels of gut-derived metabolites such as PAG and trigonelline
found in CS newborn urine (Figure 6, purple arrows). Another
interesting ﬁnding regards the signiﬁcant increase in excreted IS
in VD newborns. IS is formed in the liver from indole, a
product of intestinal tryptophan breakdown, and is known to
mediate oxidative stress in human umbilical vein endothelial
cells.50 The IS increase in VD cases is consistent with the
process involving increased oxidative stress, as reported.47,49 In
addition, the decreasing tendency of myo-inositol, found here in
common to umbilical cord blood of CS cases compared to VD,
may also relate to labor induced stress.13 The CS group also
accommodates a signiﬁcant increase in the ketone body
acetone, which may be indicative of changes in hepatic fatty
acids ß-oxidation and gluconeogenesis, consistently with a
previous report on CS-born piglets.48
Prematurity and Comparison to Other Disorders
The impact of prematurity on newborn urine was found to
involve disturbances in several diﬀerent pathways (Figure 6,
blue arrows). The changes in NMND (↑), 2-Py (↓), and 3-
aminoisobutyrate (↓) indicate a general nucleotide metabolism
Table 3. continued
LGA (n = 18) vs Controls (n = 46) Malformations (n = 9) vs Controls (n = 46)
Compound δH/ppm and multiplicity
a
Variation (effect size, p-
value) Compound δH/ppm and multiplicity
a
Variation (effect size, p-
value)
0.5−0.55 ↑ (0.76 ± 0.56, 3.61e−2)
0.57−0.60 ↑ (0.56 ± 0.56, 4.31e−2) Lactosec,f 3.28 t, 4.46 d ↑
0.64−0.70 ↑ (0.70 ± 0.56, 7.50e−2) Lysine 1.73 m ↓
0.77−0.87 ↑ (0.79 ± 0.56, 1.05e‑1) NMND 8.90 d, 8.97 d, 9.28 s ↑
0.89−0.94 ↑ (1.04 ± 0.57, 3.75e−2)
3.35−3.38 ↓(−0.66 ± 0.56, 7.50e−2) PAGc,f 7.36 t, 7.43 t ↓
6.17−6.19 ↓ (−0.49 ± 0.55, 7.50e−2) Succinate 2.41 s ↓ (−0.95 ± 0.74, 1.68e−1)
Tyrosine 6.90 d ↑
6.39−6.41 ↓ (−0.65 ± 0.56, 6.01e−2) Trigonellinec 8.84 br, 9.12 s ↑
6.43−6.45 ↓ (−0.87 ± 0.57, 3.61e−2) Xylosec 4.59 d, 5.22 d ↑
6.46−6.47 ↓ (−0.80 ± 0.56, 4.69e−2) U17 4.53 s [1.84 m] ↑ (0.77 ± 0.73, 3.30e−1)
Unassigned spectral regions
8.01−8.07 ↑ (1.30 ± 0.59, 9.65e−2) 8.40−8.42 ↑ (0.99 ± 0.74, 3.30e-1)
+ 12 unassigned spin systems and 17 spectral regions with p > 0.05 +8 unassigned spin systems and 14 spectral regions with p > 0.05
a, b,c,*See Table 2 for meaning. dPossible contribution of gender. econsistent with previous prematurity studies,18,19 fPossible contribution of
delivery mode. Ui: unassigned compound i by appearance order. Amino acids in 3-letter code, 2-Py: N-methyl-2-pyridone-5-carboxamide, DMG:
dimethylglycine, p-CS: p-cresol sulfate, 3-HBA: 3-hydroxybutyrate, 3-HIVA: 3-hydroxyisovalerate, 4-DTA: 4-deoxythreonic acid, other compounds
deﬁned in Table 2. Eﬀect size values equal or lower than error, concomitantly with p-values >0.05, are not shown.
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disturbance. NMND is formed from niacin and tryptophan to
provide pyridine nucleotides to the liver and higher excreted
NMND levels have been previously found in premature babies
and attributed to the high concentration of tryptophan in fetal
blood and its regulation after birth.19 In this work, the increase
in NMND is accompanied by a decrease in 2-Py, whereas
decreased 3-aminoisobutyrate suggests a reduction in pyrimi-
dine degradation (Figure 6). Moreover, the increase in formate
may relate to its role in de novo purine biosynthesis, through
activation by tetrahydrofolate (THF),51 the suggestion of
altered purines synthesis having been advanced before in
studies of umbilical cord blood of premature VLBW newborns.8
However, formate changes may also reﬂect gender unbalance,
as well as an involvement as precursor of TCA intermediate
malate. The latter possibility is consistent with the increases in
citrate, fumarate and succinate, and decreased cis-aconitate
(Figure 6), which suggest a TCA cycle activity enhancement in
premature babies. A derangement in energy metabolism is
further supported by the changes in ketone bodies (↓ 3-HBA
and acetone), ketogenic amino acid lysine (↑, but possibly also
gender-related), 4-DTA (↓, a product of threonine catabolism52
and related to 3-HBA53), and lactate (↓) (Figure 6). Previous
studies have associated prematurity with enhanced use of fatty
acids as a source of energy at the time of birth8 and the
decreased ketone bodies suggest their higher consumption for
TCA cycle enhancement in extra hepatic tissues, for energy
production. The decrease in lactate is consistent with a possible
enhanced use of pyruvate into the TCA cycle.
Variations in ethanolamine (↓) and myo-inositol (↑) may
reﬂect changes in the synthesis of membrane phospholipids
phosphatidylethanolamine and phosphatidylinositol (PI),
which act as lung surfactants.54 In this cohort, premature
babies were born approximately at the gestational age
characterized by enhanced PI formation (32−35 g.w.), just
before its declining until the end of gestation. Therefore,
increased urinary myo-inositol could reﬂect that temporary
higher demand for PI synthesis. However, other reasons may be
advanced for myo-inositol changes, namely a possible
contribution from gender, a relation with renal function
disturbance,18 or an indication of insulin resistance, as noted
for IUGR newborns.21 A possible relation to renal function is
supported by other indicators namely, the lower levels of
Figure 5. Volcano plots of eﬀect size vs−log(p-value) of the metabolite/resonances integrals listed in Table 3 for (a) prematurity, (b) respiratory
depression, (c) LGA newborns, and (d) malformations. Dashed lines indicates p-value = 0.05.
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creatinine, previously associated with immature tubular and
vascular structures in the kidney,55 and of methylguanidine, an
uremic toxin formed from creatinine via creatol,56 although
with a possible gender contribution. The higher IS levels in
premature newborns may be reﬂective of increased oxidative
stress57 but increased IS in urine and serum of adults has also
been interpreted as reﬂective of impaired renal function.58,59
Other signiﬁcant changes related to prematurity include 3-
hydroxyisovalerate (3-HIVA) (↑), DMA (↓) and 1-methyl-
histidine (↓), the latter two compounds being related with gut
microﬂora and the former having been proposed as a marker of
reduced biotin status.60
Comparison of the above observations with groups of term
newborns suﬀering from other abnormal conditions unveiled
that, not only prematurity seems to be characterized by a
speciﬁc urinary signature, but also that newborns aﬀected by
respiratory depression episode, LGA or malformations also
evidence their own speciﬁc metabolic signatures. This indicates
that NMR metabolomics of newborn urine is capable of
distinguishing diﬀerent conditions, in addition to detecting
general metabolic disturbances dues to generalized stress
eﬀects. Accordingly, the urinary signatures found for respiratory
depression, LGA, and malformations are also putatively
interpreted below. In relation to the newborns aﬀected by a
Figure 6. Schematic representation of the main metabolic pathways aﬀected due to gender and delivery mode and in cases of prematurity, respiratory
depression, LGA newborns and malformations, seen through newborn urine (changes noted correspond to those listed in Tables 2 and 3).
Metabolites in bold are those observed by NMR. Color code: light pink: females (vs males), purple: CS (vs VD), blue: prematurity, red: respiratory
depression, deep pink: LGA, orange: malformations. Amino acids in 3-letter code; NaMN: nicotinic acid mono nucleotide, NaAD: nicotinic acid
adenine dinucleotide, NAD+: nicotinamide adenine dinucleotide, NADP: nicotinamide dinucleotide phosphate, ADP: adenosine diphosphate,
NMND: N-methyl-nicotinamide, 2-Py: N-methyl-2-pyridone-5-carboxamide, 4-Py: N-methyl-4-pyridone-3-carboxamide, 4-DEA: 4-deoxyerythronic
acid, 4-DTA: 4-deoxythreonic acid, 3-HBA: 3-hydroxybutyrate, PAG: phenylacetylglutamine, DMA: dimethylamine, PI: phosphatidylinositol, PE:
phosphatidylethanolamine, PC: phopshatidylcholine, DMG: dimethylglycine, GAA: guanidoacetate, Hcy: homocysteine, GSH: gluthathione, THF:
tetrahydrofolate.
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respiratory depression episode at birth (depressed Apgar score
in the ﬁrst minute, but without other clinical signs of asphyxia),
a parallelism with neonatal asphyxia may be drawn to some
extent, bearing in mind that the latter implies a more severe
case of oxygen deprivation and comprises other sequelae.
Variations in glycine (↑), betaine (↑), taurine (↑), creatine (↑),
myo-inositol (↑) and 4-DEA (↓) were found to have the highest
statistical signiﬁcance (Figure 6, red arrows). Increased glycine,
an excitatory neurotransmitter, has been reported in cerebral
spinal ﬂuid (CSF) of neonates with asphyxia and HIE,61 being
suggested that perinatal asphyxia enhances glycine prouction.
The concomitant alterations in betaine, choline, creatine and
taurine are consistent with perturbation of the methionine
cycle. Regarding myo-inositol, high levels in the brain of HIE
newborns have been reported,62 this having been related to
gliosis (proliferation of astrocytes after central nervous system,
CNS, injury) and poor myelination.62 In addition, the function
of myo-inositol as precursor of lung surfactant PI may also be
important in relation to the development of the respiratory
depression episode. In the LGA cohort, varying urine
metabolites include myo-inositol (↓), DMG (↑) and 2-Py (↑)
(Figure 6, dark pink arrows). Higher myo-inositol levels have
been noted in the urine of IUGR and LGA newborns and
suggested to reﬂect altered glucose metabolism.22 Our
observation of less myo-inositol in LGA babies contradicts
previous observations, while suggesting that other eﬀects may
contribute to myo-inositol levels, for example, alterations in
lung surfactant metabolism. The higher urinary DMG and 2-Py
levels may originate from changes in methionine cycle and
nucleotides metabolism, respectively (Figure 6). Increased
DMG has been correlated with higher birth weight, in a LBW
vs normal weight cohort, due to alterations in choline
metabolism.63 Moreover, it has been suggested that alterations
in methionine metabolism could impact on purine and
pyrimidine metabolism, deoxyribonucleic acid (DNA) synthesis
and/or cell proliferation, and aﬀect fetal growth.64 This is
consistent with the noted disturbances in the tryptophan-
nicotinamide adenine dinucleotide (tryptophan-NAD+) path-
way (Figure 6) and the signiﬁcant intensity decrease of
purines/pyrimidines resonances at δ 6.0−6.5. Notably, the bile
acids region (δ 0.5−1.0)19 is signiﬁcantly increased in LGA
newborns, but no explanations for this may be advanced at this
stage. Finally, the heterogeneous malformations group seems to
evidence general eﬀects on succinate (↓), IS (↓), citrate (↓),
and 2-Py (↓) (Figure 6, orange arrows). A lower level of
succinate has also been observed in maternal urine of women
carrying malformed fetuses,32 possibly reﬂecting its underuse in
the respiratory chain and/or as an intermediate of the TCA
cycle, along with citrate, cis-aconitate and fumarate, all
decreased in this cohort (Figure 6). IS has been seen to
increase in the maternal urine of CNS malformations cases, due
to increased oxidative stress,32 however, in this cohort it may
also carry a reﬂection of delivery mode. Nucleotide metabolism,
particularly the tryptophan-NAD+ pathway, also seems to be
altered in cases of malformations, as shown by 2-Py and
NMND levels (Figure 6), the latter having been noted in the
urine of women carrying malformed fetuses.32 It is interesting
to note that, although generally distinct signatures are observed
for the four diﬀerent conditions studied (Figure 6), the increase
in NMND and the decrease in 3-HBA seem to occur
consistently (in at least three of the disorders), thus suggesting
that general stress eﬀects impact on nucleotide metabolism and
ketone body production.
■ CONCLUSIONS
This paper reports a comprehensive NMR metabolomics study
of newborn urine to study the metabolic impact of prematurity,
compared to other newborn disorders (namely respiratory
depression episode, large for gestational age and malforma-
tions) and taking into account important confounders. First,
results have shown that gender and delivery mode have
signiﬁcant impacts on urine composition and, hence, need to be
considered when subject groups are unmatched in these
respects. Subsequently, premature newborns were found to be
characterized by a wide signature of varying metabolites,
indicative of disturbances in nucleotide metabolism, lung
surfactants biosynthesis, and renal function, along with
enhancement of TCA cycle activity, fatty acids oxidation and
oxidative stress. This signature was substantially distinct from
those characterizing other disorders, since (1) newborns who
suﬀered a respiratory depression episode revealed increased
glycine excretion (possibly reﬂecting alterations in cerebral
synthesis of neurotransmitters), alterations in methionine cycle
and myo-inositol (possibly due to mild indication of possible
brain insult and/or lung surfactant biosynthesis alterations), (2)
LGA newborns showed myo-inositol changes (possibly
indicative of altered glucose handling and/or lung surfactant
metabolism), changes in methionine cycle and purines/
pyrimidines metabolism, with a suggestion of some role played
by bile acids, (3) the small heterogeneous group of
malformations seemed to share a TCA cycle slowing down
and a disturbance of nucleotides metabolism. Interestingly, in
addition to the observed signature diﬀerences, changes in
NMND and 3-HBA seems to reﬂect general metabolic eﬀects
(nucleotide metabolism and ketone body synthesis) present in
most of the disorders studied.
This work shows that NMR metabolomics is successful in
extracting detailed and largely speciﬁc information on the urine
composition of newborns aﬀected by several disorders. The
putative biochemical interpretations advanced here require
future biological demonstration and validation in large cohorts,
in order to lay the ground for the clinical use of speciﬁc
metabolic signatures as diagnostic and prognostic markers.
Regarding prematurity, in particular, this knowledge may
become useful to (1) assess the extent of the speciﬁc
consequences of the condition on each newborn, (2) correlate
to possible prenatal biomarkers found in maternal bioﬂuids and
which may be predictive of prematurity, and (3) identify and
distinguish short- and long-term eﬀects of prematurity.
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Figure S1. Q2 distributions (left) and ROC maps (right)
of true and permuted models obtained for the 1H NMR
spectra of newborn urine after variable selection of a)
female n = 23 vs male n = 23 and b) prematurity n = 17
vs controls n = 46. Q2: predictive power; TPR: true
positive rate; FPR: false positive rate. Figure S2. VIP-
wheel representation of the NMR metabolite signatures
(left) and Volcano plots of eﬀect size vs−log(p-value) of
the metabolite/resonances integrals listed in Table 2
(right) obtained for (a) gender (female vs male
newborns) and for (b) delivery mode (CS vs VD).
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Colored shade in VIP-wheel representation indicates
region typically containing resonances of bile acids
(green), aliphatic region (blue), sugar region (pink)
and aromatic region (orange). Metabolites or spectral
regions with higher VIP values are noted. *: spectral
features corresponding to large VIP values but with no
statistical relevance (p value >0.05). Figure S3. PLS-DA
scores scatter plot obtained for prematurity (blue circles,
n = 17) compared to controls (black circles, n = 46),
where symbol diameter represents (a) gestational age at
birth and (b) birth weight. Table S1. Peak assignments in
the 1H NMR spectra of newborn urine, at pH 7.00 ±
0.02. s: singlet, d: doublet, t: triplet, q: quartet, dd:
doublet of doublets, m: multiplet. a Indicates compounds
identiﬁed in newborn urine for the ﬁrst time to our
knowledge, compared to literature. Table S2. Q2
(predictive power) values and MCCV parameters
obtained for the PLS-DA models corresponding to (a)
full resolution data sets and (b) data sets obtained after
variable selection. GA: gestational age, CR: classiﬁcation
rate, Sens.: sensitivity, Spec.: speciﬁcity, Q2: cumulative
predictive power obtained by cross-validation, Q2m:
median Q2 obtained by MCCV. *Models not considered
robust principally due to poor ROC maps and/or poor
quality of Q2distributions (PDF)
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Le Gall, G.; Tea, I.; Antignac, J.-P.; Darmaun, D. Maternal and cord
blood LC-HRMS metabolomics reveal alterations in energy and
polyamine metabolism, and oxidative stress in very-low birth weight
infants. J. Proteome Res. 2013, 12, 2764−2778.
(9) Walsh, B. H.; Broadhurst, D. I.; Mandal, R.; Wishart, D. S.;
Boylan, G. B.; Kenny, L. C.; Murray, D. M. The Metabolomic Profile
of Umbilical Cord Blood in Neonatal Hypoxic Ischaemic Encephal-
opathy. PLoS One 2012, 7, e50520.
(10) Reinke, S. N.; Walsh, B. H.; Boylan, G. B.; Sykes, B. D.; Kenny,
L. C.; Murray, D. M.; Broadhurst, D. I. 1H NMR derived metabolomic
profile of neonatal asphyxia in umbilical cord serum: implications for
hypoxic ischemic encephalopathy. J. Proteome Res. 2013, 12, 4230−
4239.
(11) Longini, M.; Giglio, S.; Perrone, S.; Vivi, A.; Tassini, M.; Fanos,
V.; Sarafidis, K.; Buonocore, G. Proton nuclear magnetic resonance
spectroscopy of urine samples in preterm asphyctic newborn: A
metabolomic approach. Clin. Chim. Acta 2015, 444, 250−256.
(12) Dani, C.; Bresci, C.; Berti, E.; Ottanelli, S.; Mello, G.; Mecacci,
F.; Breschi, R.; Hu, X.; Tenori, L.; Luchinat, C. Metabolomic profile of
term infants of gestational diabetic mothers. J. Matern.-Fetal Neonat.
Med. 2014, 27, 537−542.
(13) Hashimoto, F.; Nishiumi, S.; Miyake, O.; Takeichi, H.; Chitose,
M.; Ohtsubo, H.; Ishimori, S.; Ninchoji, T.; Hashimura, Y.; Kaito, H.;
et al. Metabolomics analysis of umbilical cord blood clarifies changes in
saccharides associated with delivery method. Early Hum. Dev. 2013,
89, 315−320.
(14) Constantinou, M.; Papakonstantinou, E.; Benaki, D.; Spraul, M.;
Shulpis, K.; Koupparis, M.; Mikros, E. Application of nuclear magnetic
resonance spectroscopy combined with principal component analysis
in detecting inborn errors of metabolism using blood spots: a
metabonomic approach. Anal. Chim. Acta 2004, 511, 303−312.
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and other neurotransmitter amino acids in cerebrospinal fluid in
perinatal asphyxia and neonatal hypoxic-ischaemic encephalopathy.
Acta Paediatr. 1999, 88, 1137−1141.
(62) Fan, G.; Wu, Z.; Chen, L.; Guo, Q.; Ye, B.; Mao, J. Hypoxia-
ischemic encephalopathy in full-term neonate: correlation proton MR
spectroscopy with MR imaging. Eur. J. Radiol. 2003, 45, 91−98.
(63) Hogeveen, M.; den Heijer, M.; Semmekrot, B. A.; Sporken, J.
M.; Ueland, P. M.; Blom, H. J. Umbilical choline and related
methylamines betaine and dimethylglycine in relation to birth weight.
Pediatr. Res. 2013, 73, 783−787.
(64) Kalhan, S. C.; Marczewski, S. E. Methionine, homocysteine, one
carbon metabolism and fetal growth. Rev. Endocr. Metab. Disord. 2012,
13, 109−119.
Journal of Proteome Research Article
DOI: 10.1021/acs.jproteome.5b00977
J. Proteome Res. XXXX, XXX, XXX−XXX
O
